GET DAILY SIGNALSWhy Is Illumina (ILMN) Stock Down -12.6% Today?
Key Takeaways
- Shares of ILMN tumbled roughly 12.6% on Friday, falling from a prior close of $290.06 to around $253.50 in intraday trading.
- The primary catalyst was a "sell the news" reaction to third-quarter results, which beat estimates but revealed a decline in China revenue and continued weakness in research and applied consumables.
- Secondary drivers included a stretched valuation following a more than 150% run-up from February lows, plus an analyst price-target cut from JPMorgan.
- Broader market pressure compounded the decline, with the Nasdaq and S&P 500 trading lower in a risk-off session driven by weak earnings from other large technology names.
- Traders are watching whether the stock stabilizes after the post-earnings flush and how fourth-quarter guidance holds up amid China and tariff uncertainty.
- For additional detail on valuation and technicals, explore Price Targets, Earnings, and Forecast pages for ILMN.
- To see how AI-driven strategies are positioning across the market, explore Trending AI Robots.
Opening Summary
Illumina, Inc. (ILMN), a leading developer of DNA sequencing and genomics analysis tools used in drug discovery, clinical testing, and research, saw its stock plunge on Friday following its third-quarter earnings report. The shares dropped approximately 12.6%, falling to about $253.50 after closing the previous session at $290.06. The downward move came despite headline results that beat Wall Street expectations, as investors focused instead on softness in China, declining research consumables, and a valuation that had priced in perfection.
Earnings Results: A Beat Overshadowed by China and Consumables Weakness
Illumina reported adjusted earnings of $1.44 per share, surpassing the $1.36 consensus, while revenue excluding tariff refunds reached $1.17 billion, slightly above the $1.15 billion estimate. Reported revenue came in at $1.13 billion, up 4.2% year over year. The company also raised its full-year 2026 outlook, lifting revenue guidance to $4.64 billion to $4.66 billion and adjusted EPS guidance to $5.40 to $5.45.
Despite the upbeat top-line figures, investors zeroed in on more concerning details. China revenue declined 0.1% during the quarter, signaling that geopolitical and regulatory headwinds in a key market were not easing. Meanwhile, research and applied consumables fell 6% organically, reflecting persistent softness in academic and commercial research spending. Management also reiterated expectations for mid-to-high single-digit declines in research and applied consumables for the full year, undercutting the bullish narrative.
Valuation and a "Sell the News" Reaction
The sharp decline also reflected how far ILMN had run ahead of the report. After hitting a 2026 low near $112.65 in February, the stock had surged more than 150% into the print and reached a four-year high earlier in the month. That extended rally left shares trading at a premium that made even a technically positive quarter vulnerable to profit-taking. Tariff confusion also weighed on sentiment, as the quarter's results included benefits from tariff refunds that investors viewed as non-recurring, muddying the underlying growth picture.
Analyst Reactions
Analyst commentary added to the downward pressure. JPMorgan lowered its price target on the stock to $300 from $320, citing a more opaque near-term growth outlook. Other analysts maintained more cautious stances, with some holding ratings despite acknowledging that management is executing on its multi-year growth strategy. The mixed signals left investors questioning the pace of future acceleration as the NovaSeq X platform transition matures.
Market Context and Trading Activity
The selloff occurred against a broadly negative backdrop. The Nasdaq Composite opened sharply lower, pressured by disappointing results from other large technology companies, while the S&P 500 also traded in the red. The risk-off tone particularly hit high-multiple growth names, amplifying the post-earnings decline in ILMN. Trading volume was elevated as the market digested the results, consistent with a significant earnings-driven repricing of a stock that had been among the sector's strongest performers.
What Comes Next for ILMN
Looking ahead, investors will focus on whether Illumina can demonstrate sustained growth in its clinical business while stabilizing research and applied demand. The company guided fourth-quarter revenue to $1.22 billion to $1.24 billion and adjusted EPS to $1.51 to $1.56, but deferred detailed 2027 guidance until its next report. Key risks include ongoing China headwinds, the trajectory of research spending, and the fading tailwind from the NovaSeq X transition. Conversely, expanding clinical sequencing adoption and the company's early-stage AI and data initiatives remain potential long-term catalysts.
Trending AI Robots
Tickeron offers hundreds of AI-powered trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in its curated Trending AI Robots section. These bots vary by strategy, timeframe, performance metrics, and traded symbols, giving traders a range of automated approaches to explore. For those seeking data-driven signals across dynamic markets like the one that shaped ILMN's move today, the page offers a useful starting point.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Aroon Indicator for ILMN shows an upward move is likely
ILMN's Aroon Indicator triggered a bullish signal on October 15, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 214 similar instances where the Aroon Indicator showed a similar pattern. In 178 of the 214 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +3.79% 3-day Advance, the price is estimated to grow further. Considering data from situations where ILMN advanced for three days, in 204 of 271 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
ILMN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 10-day RSI Indicator for ILMN moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In 19 of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at 73%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 47 of 68 cases where ILMN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 69%.
The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ILMN as a result. In 66 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 69%.
The Moving Average Convergence Divergence Histogram (MACD) for ILMN turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 56 similar instances when the indicator turned negative. In 39 of the 56 cases the stock turned lower in the days that followed. This puts the odds of success at 70%.
ILMN moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ILMN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 1 (best 1 - 100 worst), indicating outstanding price growth. ILMN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 31 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 86 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (12.556) is normal, around the industry mean (67.473). P/E Ratio (43.783) is within average values for comparable stocks, (2.957). Projected Growth (PEG Ratio) (3.355) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (7.843) is also within normal values, averaging (9.775).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ILMN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of integrated systems for the analysis of genetic variation and function
Industry MedicalSpecialties
Advertisement